Vivus: pharma partner "critical" for Qsymia
This article was originally published in Scrip
Executive Summary
Vivus's stock price inched higher during the past month as investors reacted to incrementally positive news for Qsymia (phentermine and topiramate) and the stock closed up 4.2% on 13 May based on a letter to shareholders that reaffirmed plans to engage a major pharmaceutical partner to market the company's weight loss drug.